Green Cross’s ‘Rixubis’ enters domestic hemophilia B market
The Green Cross and Baxalta alliance will target the hemophilia B market.
According to the industry concerned on the 9th, Green Cross will take in charge of domestic distribution and sales of ‘Rixubis,’ a new hemophilia B treatment, as well as the hemophilia A treatment ‘Advate.’
Rixubis has ...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
